Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection

摘要

Ribavirin and/or alpha interferon are used in the manufacture of a pharmaceutical composition for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA by a method comprising administrating an effective amount of ribavirin and/alpha interferon in association with an effective amount of interferon alpha and/or ribavirin for a time period of 40-50 weeks. The patient is one having failed to response to a previous course of interferon alpha therapy and has a viral load of greater than 2 million copies per ml of serum as measured by HCV-RNA quantitative PCR of a HCV genotype type 1 infection.